Purpose & when to use

Bioaerosol Efficacy Testing Room studies measure how room-scale or in-duct devices reduce airborne microbial concentrations over time. Controlled chambers, duct sections, nebulized organism surrogates, viable impingers, filter collection, and culture, qPCR, or droplet digital PCR (ddPCR) endpoints support ISO 17025 records and ASHRAE 241 or AHAM AC-1 aligned performance claims:

  1. Room air cleaner benchmarking under ASHRAE 241 context, using chamber release, viable sampling, and log reduction curves for portable or fixed air-treatment devices.
  2. UVGI design verification for room or duct systems, using ISO 17025 records, UV dose logging, airflow data, and viable recovery to compare operating modes.
  3. In-duct HVAC add-on evaluation aligned to ASTM E3273 or ISO 16000-36, using defined flow, organism recovery, and device-off controls for reduction claims.
  4. EPA OPPT claim support for antimicrobial or air-treatment products, using organism selection, recovery validation, and replicate chamber runs matched to the claim language.
  5. AHAM AC-1 adjacent air cleaner studies under ISO 17025 records, using controlled bioaerosol challenges and device-off decay baselines to translate particle CADR concepts into microbial reduction data.

Use room bioaerosol efficacy testing when the decision depends on measured microbial reduction under defined airflow, mixing, RH, and temperature conditions. The study plan fixes the organism panel, chamber or duct configuration, endpoints, and aligned standards before testing begins.

Built for room and duct air-treatment devices

Bioaerosol efficacy studies serve air-treatment products where microbial reduction, airflow, and operating mode all affect the claim. Device setup is mapped to ASHRAE, AHAM, ASTM, EPA, or ISO expectations during planning.

  • Air cleanersPortable and room-scale units
  • UVGI unitsRoom and in-duct systems
  • HVAC add-onsDuct-mounted treatment devices
  • Hybrid devicesFiltration plus active treatment
  • Control systemsMode and airflow logic

Instrumentation & measurement ranges

Platform selection follows the device geometry, organism panel, endpoint sensitivity, and airflow frame.

1 – 30 mchamber-scale

Room chambers and duct sections

Controlled enclosures or duct runs define device placement, release location, mixing strategy, airflow, and sampling positions for room-scale or in-duct efficacy studies.

0.1 – 10 mL/minliquid-feed

Bioaerosol nebulizers and generators

Generate organism or surrogate challenges at defined release conditions, with background checks and recovery controls matched to the selected endpoint.

1 – 30 L/minsampler-flow

Viable samplers and filter trains

Impingers, filter holders, and timed collection trains capture airborne organisms at baseline and post-treatment intervals for concentration decay analysis.

10 – 10000000 copiesquantitation

Culture, qPCR, and ddPCR endpoints

Culture and molecular endpoints convert collected samples into viable counts, gene copies, or absolute copy number depending on organism and claim frame.

20 – 80 RHcondition-control

Environmental and UV measurement

Temperature, relative humidity, airflow, device mode, and UV irradiance or dose are logged where they affect recovery, inactivation, or comparison across runs.

Test method options

MethodStrengthsTradeoffAligned with
Room infectious aerosol reduction study
  • ASHRAE 241 aligned chamber data links microbial reduction to room-scale air-treatment decisions and equivalent clean airflow concepts.
  • Device-off controls and timed viable sampling distinguish natural decay from device-driven reduction across operating modes.
Mixing, room volume, organism recovery, and baseline decay must be controlled tightly before log reduction values can be compared.
ASHRAE 241ISO 17025
Portable air cleaner microbial efficacy study
  • AHAM AC-1 aligned chamber structure supports portable air-cleaner comparisons using defined release, mixing, and decay intervals.
  • Culture, qPCR, or ddPCR endpoints allow organism-specific reporting where particle-only CADR data are not enough.
AHAM AC-1 is not a complete microbial-kill protocol, so organism recovery and endpoint validation need added study controls.
AHAM AC-1ISO 17025
Duct or claim-support efficacy study
  • ASTM E3273, EPA OPPT, and ISO 16000-36 alignment can support air-treatment or antimicrobial claim files when the device and organism fit.
  • Duct fixtures, UV dose logging, and airflow records help compare in-duct units, UVGI systems, and hybrid devices under installed-use conditions.
Regulatory fit depends on claim language, organism selection, biosafety limits, and whether the device is room-scale, in-duct, or surface-adjacent.
ASTM E3273EPA OPPTISO 16000-36

Setup configurations

Every room efficacy study starts by fixing the device placement, challenge organism, release strategy, airflow, and endpoint. The configuration determines how much of the observed decay is attributable to the device rather than background loss, sampler behavior, or environmental drift. These setup dimensions are locked in the protocol:

Device interfaces

Room placement, duct insertion, UVGI mounting, or fixture adaptation documented with device mode, flow path, and distance from release and sampling points.

Exposure profile

Defined organism release, mixing time, device-on interval, sampling schedule, and run duration matched to the expected reduction rate.

Environmental controls

Temperature, RH, airflow, background aerosol, and UV dose or irradiance logged where they affect survival, transport, or inactivation.

Sample numbers

Replicate device-on runs, device-off controls, blanks, and background checks sized to the study decision and expected variability.

Calibration & verification

Sampler flow, nebulizer output, assay controls, environmental sensors, and UV meters verified before or during each campaign.

Methods anchored to the standards that matter

Room efficacy studies separate the accredited laboratory quality anchor from aligned performance frames. The four anchors below define the study records, chamber controls, and reporting language.

  • ISO 17025AccreditedTesting-laboratory competence, calibration traceability, method records, and data review.
  • ASHRAE 241AlignedInfectious aerosol risk management and equivalent clean airflow context.
  • AHAM AC-1AlignedPortable air cleaner chamber-performance context for room device studies.
  • ASTM E3273AlignedAirborne microorganism reduction context for chamber efficacy claims.

Key data outputs & reporting

Bioaerosol efficacy reports connect device operation to measured airborne microbial concentration over time. Outputs include baseline decay, device-on decay, log reduction, replicate statistics, assay recovery, environmental conditions, UV or airflow records where used, and QA / QC evidence needed to explain which claims the data can support for technical files, claim review, or design decisions.

Primary outputs

  • Airborne microbial concentration versus time for device-on and device-off runs, with sampling interval, endpoint, and recovery basis stated.
  • Log reduction versus time and condition, including operating mode, airflow, UV dose where applicable, and replicate statistics.
  • Assay and sampler performance summaries covering blanks, recovery checks, standard curves, extraction controls, and quantitation limits.
  • Environmental and configuration records tied to each run, including RH, temperature, chamber or duct geometry, release position, and device settings.

Deliverables

#FormatContents
01PDF reportMethods, conditions, controls, reduction results, QA / QC, and study interpretation.
02CSV / XLSX datasetsRun-level concentrations, log reductions, recovery checks, and environmental records.
03FiguresDecay curves, log reduction plots, condition overlays, and mode comparisons.

QA / QC & data integrity

Room bioaerosol studies run with controls that distinguish device efficacy from chamber loss, assay variability, and sampling artifacts. Records are maintained under the ISO 17025 quality system from organism receipt or preparation through final data review, with traceability for instruments, samples, analytical endpoints, and reported calculations.

Device-off controls and background runs define natural decay and pre-challenge chamber conditions.

Sampler blanks, media blanks, and extraction controls track contamination and assay background.

Recovery checks for impingers, filters, extraction steps, and culture or molecular assays support quantitation limits.

Replicate runs and repeated sequences quantify variability across device modes, organisms, or airflow settings.

Calibration records cover sampler flow, airflow, RH, temperature, and UV radiometers when UVGI is tested.

Chain of custody tracks organisms, collected samples, extracts, devices, and raw instrument files.

Why ARE Labs

ARE Labs connects technical topics to practical study design, method selection, controlled aerosol work, and reportable evidence without turning technical pages into sales pages.

Reviewed byJamie Balarashti (25 yrs - cascade & inhalation methods) - Weston Schaper (7 yrs - real-time sizing & nanoparticle work)
17025Accredited testing
900+Studies Performed
17+Years in operation
300+Clients supported

Common questions

Quick answers to the questions air-treatment developers, UVGI teams, HVAC engineers, and antimicrobial product teams ask when scoping room bioaerosol efficacy studies. Topics include organism choice, chamber versus duct setup, log reduction calculations, controls, UV dose records, molecular endpoints, and deliverables. Reach out if your device geometry, claim language, or biosafety frame does not match the examples below.

Q.Which organisms can you use?
A.We select organisms or surrogates that match the claim, biosafety requirements, and endpoint sensitivity. The plan includes recovery checks so the sampler and assay can support the intended log reduction calculation.
Q.How is log reduction calculated?
A.Log reduction is calculated from measured airborne concentration over time, comparing device-on runs with device-off decay controls. Sampling volume, recovery, endpoint sensitivity, and replicate statistics are included in the result.
Q.Can you test a duct device instead of a room device?
A.Yes. Duct studies are fit for in-duct UVGI, filtration, or active treatment devices when the installed condition is a controlled flow path rather than an open room.
Q.Do you support UVGI efficacy studies?
A.Yes. UVGI studies can include UV irradiance or dose logging, airflow records, device mode settings, and viable recovery endpoints so reduction can be interpreted against exposure conditions.
Q.What do I receive after testing?
A.You receive a PDF report, CSV or XLSX datasets, and figures showing concentration decay, log reduction, controls, recovery checks, environmental conditions, and study interpretation.